JP2018516984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516984A5 JP2018516984A5 JP2018513745A JP2018513745A JP2018516984A5 JP 2018516984 A5 JP2018516984 A5 JP 2018516984A5 JP 2018513745 A JP2018513745 A JP 2018513745A JP 2018513745 A JP2018513745 A JP 2018513745A JP 2018516984 A5 JP2018516984 A5 JP 2018516984A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hpv
- composition according
- item
- rnp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 53
- 101710163270 Nuclease Proteins 0.000 claims description 34
- 241000701806 Human papillomavirus Species 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- 102000004389 Ribonucleoproteins Human genes 0.000 claims description 16
- 108010081734 Ribonucleoproteins Proteins 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 16
- 108020005004 Guide RNA Proteins 0.000 claims description 13
- 108091033409 CRISPR Proteins 0.000 claims description 11
- 210000002510 keratinocyte Anatomy 0.000 claims description 10
- 239000002502 liposome Substances 0.000 claims description 10
- 101150071673 E6 gene Proteins 0.000 claims description 8
- 101150013359 E7 gene Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 229920006317 cationic polymer Polymers 0.000 claims description 3
- 239000002082 metal nanoparticle Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000002073 nanorod Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 2
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000010459 TALEN Methods 0.000 description 3
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- -1 cationic lipid Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168188P | 2015-05-29 | 2015-05-29 | |
| US62/168,188 | 2015-05-29 | ||
| PCT/US2016/034627 WO2016196282A1 (en) | 2015-05-29 | 2016-05-27 | Compositions and methods for cell targeted hpv treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516984A JP2018516984A (ja) | 2018-06-28 |
| JP2018516984A5 true JP2018516984A5 (enExample) | 2019-06-27 |
Family
ID=56137529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513745A Pending JP2018516984A (ja) | 2015-05-29 | 2016-05-27 | 細胞を標的にしたｈｐｖ処置のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20160346360A1 (enExample) |
| EP (1) | EP3324999A1 (enExample) |
| JP (1) | JP2018516984A (enExample) |
| CA (1) | CA3000155A1 (enExample) |
| GB (1) | GB2543873A (enExample) |
| WO (1) | WO2016196282A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| AU2014207618A1 (en) | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| EP4079847A1 (en) | 2014-07-30 | 2022-10-26 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
| GB2543873A (en) * | 2015-05-29 | 2017-05-03 | Agenovir Corp | Compositions and methods for cell targeted HPV treatment |
| EP3355954A4 (en) * | 2015-09-29 | 2020-01-08 | Agenovir Corporation | METHODS AND COMPOSITIONS OF ADMINISTRATION |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and uses thereof |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
| WO2018118585A1 (en) * | 2016-12-22 | 2018-06-28 | Agenovir Corporation | Antiviral compositions |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| JP2020513783A (ja) * | 2017-01-18 | 2020-05-21 | エクシジョン バイオセラピューティクス インコーポレイテッド | Ｃｒｉｓｐｒ |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| CA3057330A1 (en) * | 2017-03-21 | 2018-09-27 | Anthony P. Shuber | Treating cancer with cas endonuclease complexes |
| GB2575930A (en) | 2017-03-23 | 2020-01-29 | Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
| CN110678548A (zh) * | 2017-03-31 | 2020-01-10 | 埃吉诺维亚公司 | 抗病毒治疗剂 |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| DE112020001342T5 (de) | 2019-03-19 | 2022-01-13 | President and Fellows of Harvard College | Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
| US20230044432A1 (en) * | 2019-12-03 | 2023-02-09 | Université de Liège | Pooled Crispr Inverse PCR Sequencing (PCIP-Seq): Simultaneous Sequencing of Viral Insertion Points and the Integrated Viral Genomes with Long Reads |
| CN111018956B (zh) * | 2019-12-30 | 2020-10-09 | 鼓润(武汉)医疗科技有限公司 | 一种靶向敲除hpv urr基因的dna结合蛋白、系统及其应用 |
| GB2614813B (en) | 2020-05-08 | 2025-05-07 | Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| CN113952475B (zh) * | 2021-09-27 | 2025-03-11 | 中国人民解放军陆军军医大学 | 淋巴细胞和介导crispr系统的纳米复合物联合在制备治疗宫颈癌药物中的应用 |
| CN116004716A (zh) * | 2022-09-09 | 2023-04-25 | 华中农业大学 | 一种复制型dCas9-FokI系统进行高效基因编辑的方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5580571A (en) | 1991-10-15 | 1996-12-03 | Hostetler; Karl Y. | Nucleoside analogues |
| SE9200951D0 (sv) | 1992-03-27 | 1992-03-27 | Kabi Pharmacia Ab | Pharmaceutical composition containing a defined lipid system |
| US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
| US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| JPH09500013A (ja) | 1993-06-01 | 1997-01-07 | ライフ・テクノロジーズ・インコーポレイテッド | カチオン性脂質による遺伝子免疫 |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| USRE39229E1 (en) | 1994-08-20 | 2006-08-08 | Gendaq Limited | Binding proteins for recognition of DNA |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| GB0526211D0 (en) | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| WO2007139898A2 (en) | 2006-05-25 | 2007-12-06 | Sangamo Biosciences, Inc. | Variant foki cleavage half-domains |
| US20110023144A1 (en) | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in amyotrophyic lateral sclerosis disease |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| AU2013359199C1 (en) * | 2012-12-12 | 2021-06-17 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| EP4481048A3 (en) | 2012-12-17 | 2025-02-26 | President and Fellows of Harvard College | Rna-guided human genome engineering |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| AU2014228981B2 (en) | 2013-03-15 | 2019-11-28 | The General Hospital Corporation | Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing |
| WO2014165349A1 (en) * | 2013-04-04 | 2014-10-09 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
| WO2014204725A1 (en) * | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| US9925248B2 (en) * | 2013-08-29 | 2018-03-27 | Temple University Of The Commonwealth System Of Higher Education | Methods and compositions for RNA-guided treatment of HIV infection |
| US9526784B2 (en) * | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| EP4372090A3 (en) * | 2013-11-07 | 2024-08-07 | Editas Medicine, Inc. | Crispr-related methods and compositions with governing grnas |
| CA2940084A1 (en) * | 2014-02-18 | 2015-08-27 | Duke University | Compositions for the inactivation of virus replication and methods of making and using the same |
| US10507232B2 (en) * | 2014-04-02 | 2019-12-17 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of latent viral infection |
| JP2017518372A (ja) * | 2014-05-30 | 2017-07-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 潜伏性ウイルス感染用の処置剤を送達するための組成物および方法 |
| JP2018516596A (ja) * | 2015-05-29 | 2018-06-28 | アジェノビア コーポレーション | 抗ウイルスの方法および組成物 |
| GB2543873A (en) * | 2015-05-29 | 2017-05-03 | Agenovir Corp | Compositions and methods for cell targeted HPV treatment |
| CA3000189A1 (en) * | 2015-05-29 | 2016-12-08 | Agenovir Corporation | Compositions and methods to treat viral infections |
-
2016
- 2016-05-27 GB GB1609438.5A patent/GB2543873A/en not_active Withdrawn
- 2016-05-27 JP JP2018513745A patent/JP2018516984A/ja active Pending
- 2016-05-27 WO PCT/US2016/034627 patent/WO2016196282A1/en not_active Ceased
- 2016-05-27 US US15/166,936 patent/US20160346360A1/en not_active Abandoned
- 2016-05-27 CA CA3000155A patent/CA3000155A1/en not_active Abandoned
- 2016-05-27 EP EP16730570.5A patent/EP3324999A1/en not_active Withdrawn
-
2018
- 2018-12-18 US US16/224,591 patent/US20190201501A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516984A5 (enExample) | ||
| JP2018516983A5 (enExample) | ||
| US20230167425A1 (en) | Rna guided eradication of varicella zoster virus | |
| EP3417062B1 (en) | Excision of retroviral nucleic acid sequences | |
| US9981020B2 (en) | Methods and compositions for RNA-guided treatment of HIV infection | |
| JP2017518075A5 (enExample) | ||
| US20190010518A1 (en) | Compositions and Methods of Delivering Treatments for Latent Viral Infections | |
| CN108883201A (zh) | Rna指导的治疗hiv感染的方法和组合物 | |
| JP2019512458A (ja) | Ｒｎａによって誘導された、ヒトｊｃウイルス及び他のポリオーマウイルスの根絶 | |
| WO2016150336A1 (zh) | 一种CRISPR-Cas9系统及其制备方法和应用 | |
| JP2017518372A5 (enExample) | ||
| CN108778343A (zh) | 利用cpf1进行rna向导的基因编辑的方法和组合物 | |
| WO2018112470A1 (en) | Co-delivery of nucleic acids for simultaneous suppression and expression of target genes | |
| CN105518149A (zh) | 靶细胞内治疗性蛋白的靶向产生的系统和方法 | |
| Avila et al. | Gene delivery and immunomodulatory effects of plasmid DNA associated with Branched Amphiphilic Peptide Capsules | |
| Abbaszadeh-Goudarzi et al. | Targeted delivery of CRISPR/Cas13 as a promising therapeutic approach to treat SARS-CoV-2 | |
| CN118973610A (zh) | 通过中断细胞和病毒受体相互作用来阻断asfv感染的方法 | |
| JP2008531672A5 (enExample) | ||
| Zuo et al. | Nuclear‐Targeting Delivery of CRISPRa System for Upregulation of β‐Defensin against Virus Infection by Dexamethasone and Phenylalanine Dual‐Modified Dendrimer | |
| Tan et al. | CRISPR/Cas9-Mediated Genome Editing: Current Status | |
| Dev et al. | Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics: CRISPR/Cas9 in antiviral therapeutics | |
| Nunes | Development of cationic polymeric nanoparticles for plasmid DNA vaccine delivery | |
| Dev et al. | Letters in Animal Biology | |
| Liu et al. | Towards the Elimination of Infectious HPV: Exploiting CRISPR/Cas Innovations | |
| HK40000290A (en) | Excision of retroviral nucleic acid sequences |